Rigel Pharmaceuticals Inc
NASDAQ:RIGL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its 3-Year Average (5.1), the stock would be worth $21.06 (31% downside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 7.4 | $30.46 |
0%
|
| 3-Year Average | 5.1 | $21.06 |
-31%
|
| 5-Year Average | 5.1 | $21.06 |
-31%
|
| Industry Average | 16.6 | $68.78 |
+126%
|
| Country Average | 13.3 | $55.11 |
+81%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Rigel Pharmaceuticals Inc
NASDAQ:RIGL
|
557.9m USD | 7.4 | 1.5 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -211 714.7 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
354.5B USD | 18.7 | 85.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.5B USD | 18.9 | 24.4 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
164.9B USD | 16.5 | 19.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
111.2B USD | 30.5 | 28 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -531.3 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.9B USD | 16.1 | 17.8 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42.4B EUR | 122.8 | 38.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -85.8 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.3B AUD | 11.8 | 30.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 8.8 |
| Median | 13.3 |
| 70th Percentile | 20.1 |
| Max | 3 188 432.5 |
Other Multiples
Rigel Pharmaceuticals Inc
Glance View
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company is headquartered in South San Francisco, California and currently employs 165 full-time employees. The company went IPO on 2000-11-29. The firm is engaged in discovering, developing and providing small molecule drugs that improve the lives of patients with hematologic disorders, cancer and rare immune diseases. The firm's research focuses on signaling pathways that are critical to disease mechanisms. The firm's product, TAVALISSE (fostamatinib disodium hexahydrate) tablets, the spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia (ITP). The Company’s product is also commercially available in Europe, the United Kingdom (UK) (TAVLESSE) and Canada (TAVALISSE) for the treatment of chronic ITP in adult patients. Its clinical programs include its interleukin receptor-associated kinase (IRAK) inhibitor program and a receptor-interacting serine/threonine-protein kinase (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company (Lilly).
